Hudson Bay Capital Management
ASBP

Hudson Bay Capital Management’s Aspire Biopharma ASBP Stock Holding History

Hudson Bay Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-125
Closed -$1.66M – 982
2024
Q1 		$1.66M Hold
125
– – 0.01% 487
2023
Q4 		$1.64M Hold
125
– – 0.01% 476
2023
Q3 		$1.75M Hold
125
– – 0.01% 502
2023
Q2 		$1.57M Sell
125
-42
-25% -$527K 0.01% 532
2023
Q1 		$2.1M Hold
167
– – 0.02% 512
2022
Q4 		$2.06M Hold
167
– – 0.02% 591
2022
Q3 		$2.03M Hold
167
– – 0.02% 719
2022
Q2 		$2M Buy
+167
New +$2M 0.02% 787

Other funds holding ASBP

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hudson Bay Capital Management's ASBP Position: Q2 2024 in Review

Hudson Bay Capital Management sold out of Aspire Biopharma (ASBP) in Q2 2024, closing a stake of 125 shares — an estimated $1.66M sold.

Hudson Bay Capital Management first reported a position in ASBP in Q2 2022 and held it in 8 quarters. The position peaked at $2.1M in Q1 2023. 3 funds tracked by Wall St. Rank hold ASBP as of Q2 2024.

  • Hudson Bay Capital Management reported no remaining Aspire Biopharma position as of Q2 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 125 Aspire Biopharma shares in Q2 2024, an estimated $1.66M.
  • Hudson Bay Capital Management first reported a position in Aspire Biopharma in Q2 2022 and held it in 8 quarters.
  • Hudson Bay Capital Management's Aspire Biopharma position peaked at $2.1M in Q1 2023.
  • 3 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2024.

Based on Hudson Bay Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.